EGFR and adenocarcinoma: Approximately 50% of Chinese patients with adenocarcinoma have EGFR mutations, and this rate is significantly higher than among Caucasians.23 In this context, the use of ICIs remains controversial for patients harboring EGFR mutation and resistance to TKIs.